HMG-coA reductase inhibitors: Lipid-lowering and beyond

Esther Lutgens; Mat J.A.P. Daemen

doi:10.1016/j.ddstr.2004.09.005

HMG-coA reductase inhibitors: Lipid-lowering and beyond

Esther Lutgens, Mat J.A.P. Daemen

Cardiovascular Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

3-Hydroxy 3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors (statins) are the primary treatment in the management of atherosclerotic vascular disease. The benefits of statin treatment are believed to result from their capacity to lower LDL-cholesterol (LDL-C). However, lowering cholesterol alone cannot explain all of the beneficial effects of statin treatment. Recent findings suggest that statins invoke a generalized anti-inflammatory action.

Original language	English (US)
Pages (from-to)	189-194
Number of pages	6
Journal	Drug Discovery Today: Therapeutic Strategies
Volume	1
Issue number	2
DOIs	https://doi.org/10.1016/j.ddstr.2004.09.005
State	Published - Oct 2004

ASJC Scopus subject areas

Molecular Medicine
Pharmacology
Drug Discovery

Access to Document

10.1016/j.ddstr.2004.09.005

Cite this

@article{418ebfa33c59481a837a0c580f8f7915,

title = "HMG-coA reductase inhibitors: Lipid-lowering and beyond",

abstract = "3-Hydroxy 3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors (statins) are the primary treatment in the management of atherosclerotic vascular disease. The benefits of statin treatment are believed to result from their capacity to lower LDL-cholesterol (LDL-C). However, lowering cholesterol alone cannot explain all of the beneficial effects of statin treatment. Recent findings suggest that statins invoke a generalized anti-inflammatory action.",

author = "Esther Lutgens and Daemen, {Mat J.A.P.}",

year = "2004",

month = oct,

doi = "10.1016/j.ddstr.2004.09.005",

language = "English (US)",

volume = "1",

pages = "189--194",

journal = "Drug Discovery Today: Therapeutic Strategies",

issn = "1740-6773",

publisher = "Elsevier Limited",

number = "2",

}

TY - JOUR

T1 - HMG-coA reductase inhibitors

T2 - Lipid-lowering and beyond

AU - Lutgens, Esther

AU - Daemen, Mat J.A.P.

PY - 2004/10

Y1 - 2004/10

N2 - 3-Hydroxy 3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors (statins) are the primary treatment in the management of atherosclerotic vascular disease. The benefits of statin treatment are believed to result from their capacity to lower LDL-cholesterol (LDL-C). However, lowering cholesterol alone cannot explain all of the beneficial effects of statin treatment. Recent findings suggest that statins invoke a generalized anti-inflammatory action.

AB - 3-Hydroxy 3-methylglutaryl coenzyme A (HMG-coA) reductase inhibitors (statins) are the primary treatment in the management of atherosclerotic vascular disease. The benefits of statin treatment are believed to result from their capacity to lower LDL-cholesterol (LDL-C). However, lowering cholesterol alone cannot explain all of the beneficial effects of statin treatment. Recent findings suggest that statins invoke a generalized anti-inflammatory action.

UR - http://www.scopus.com/inward/record.url?scp=13344270284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13344270284&partnerID=8YFLogxK

U2 - 10.1016/j.ddstr.2004.09.005

DO - 10.1016/j.ddstr.2004.09.005

M3 - Review article

AN - SCOPUS:13344270284

SN - 1740-6773

VL - 1

SP - 189

EP - 194

JO - Drug Discovery Today: Therapeutic Strategies

JF - Drug Discovery Today: Therapeutic Strategies

IS - 2

ER -

HMG-coA reductase inhibitors: Lipid-lowering and beyond

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this